• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

AABB Conference on Secondary Bacterial Screening of Platelets

August 24, 2012

In a one-day public conference held in July 2012, members from AABB and others in the transfusion medicine community discussed the risks posed by bacterial contamination of platelets and the potential benefits, costs, and efficacy of secondary bacterial screening tests. Previous studies have estimated that between 1 in 3,000 to 1 in 5,000 apheresis platelet units are infected with bacteria, despite being screened as non-contaminated during early culture testing. Although many transfusion recipients are unaffected by these contaminants, other patients can experience sepsis, shock, and even death. Prominent figures at the conference included, Dr. Darrell J. Triulzi, AABB President, Dr. Jay Epstein, director of the Food and Drug Administration’s Office of Blood Research and Review, and Dr. Richard Benjamin, chief medical officer of the American Red Cross. Although speakers noted that there has been a significant decrease in bacterial contamination since the implementation of AABB’s standard 5.1.5.1 in 2003, which requires all blood centers to “limit and detect” bacteria, they suggested considering use of further point-of-issue testing to reduce residual risk. Conference attendees also discussed the Verax Pan Genera Detection (PGD) test, other products to detect bacterial contamination of platelets, and the financial implications of additional secondary screening. The AABB Bacterial Contamination Task Force presented a preliminary analysis estimating the cost in the United States to test all apheresis platelets by PGD to be $70 million, or $117,439 per positive sample. It was not clear whether there is enough data to establish a new standard for secondary testing of platelets for bacterial contamination and further work by the AABB Bacterial Contamination Task Force will be completed.   

Reference:

“Public Conference – Secondary Bacterial Screening of Platelet Components.” Meetings and Events. AABB. Web. 23 Aug. 2012. <http://www.aabb.org/events/conference/Pages/conf.aspx>.

Filed Under

  • News
  • Platelet Transfusion
  • Policy and Guidelines
  • Quality Control and Regulatory
  • Transfusion Transmitted Infections

Recommended

  • Donor Interventions Increase Donor’s Return for Future Donations

  • Prediction of Vasovagal Reactions in Whole Blood Donors Using a Scoring System

  • RBCeq: A Novel, User-Friendly, Algorithm for Genetic Blood Typing

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley